Therapy Response and Survival of 182 Patients With Ann Arbor Stage II-IV High-Grade Malignant B-Cell Lymphomas of the Kiel Classification1,2 Treated by the COP-BLAM/IMVP-16 Regimen5
| . | CB . | B-IB . | B-ALC . |
|---|---|---|---|
| . | n (%) . | n (%) . | n (%) . |
| Total n | 127 (70) | 33 (18) | 22 (12) |
| Complete remission rate* | |||
| Total | |||
| by cycle no. | 72 (57) | 14 (42) | 10 (45) |
| Rapid 3 | 60 (47) | 12 (36) | 5 (23) |
| Rapid and maintained 3 → 7 | 52 (41) | 9 (27) | 4 (18) |
| Delayed → 7 | 21 (17) | 5 (15) | 6 (27) |
| Early relapse 3 → 7 | 6 (5) | 3 (9) | 1 (5) |
| Total relapse rate† | 21 (29) | 10 (70) | 3 (30) |
| Median survival | |||
| Overall | (not reached) | 16 mo | 20 mo |
| Relapse-free | (not reached) | 8 mo | (not reached) |
| . | CB . | B-IB . | B-ALC . |
|---|---|---|---|
| . | n (%) . | n (%) . | n (%) . |
| Total n | 127 (70) | 33 (18) | 22 (12) |
| Complete remission rate* | |||
| Total | |||
| by cycle no. | 72 (57) | 14 (42) | 10 (45) |
| Rapid 3 | 60 (47) | 12 (36) | 5 (23) |
| Rapid and maintained 3 → 7 | 52 (41) | 9 (27) | 4 (18) |
| Delayed → 7 | 21 (17) | 5 (15) | 6 (27) |
| Early relapse 3 → 7 | 6 (5) | 3 (9) | 1 (5) |
| Total relapse rate† | 21 (29) | 10 (70) | 3 (30) |
| Median survival | |||
| Overall | (not reached) | 16 mo | 20 mo |
| Relapse-free | (not reached) | 8 mo | (not reached) |